Gene Editing Stocks Lag On Clinical Setbacks, Rising Yields. Time To Buy?
Trefis Team, Contributor,
Trefis Team, Contributor
Our indicative theme of Gene Editing stocks remains down by about 11% year-to-date, meaningfully underperforming the S&P 500 which is up by about 19% over the same period. In fact, if we exclude a single stock Intellia Therapeutics, which is up by about 2.4x …